Previous 10 | Next 10 |
2024-04-29 06:32:13 ET Summary iShares U.S. Tech Breakthrough Multisector ETF owns a diversified portfolio of U.S. large-cap stocks benefiting from breakthrough technologies. The Fund has generally outperformed the S&P 500 in bull markets but underperformed in bear markets sin...
2024-04-26 15:56:40 ET Summary Shares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT. Vimseltinib is expected to make significant progress in the TGCT indication, as the only approved therapy is ...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-25 15:30:12 ET Image source: The Motley Fool. Merck (NYSE: MRK) Q1 2024 Earnings Call Apr 25, 2024 , 9:00 a.m. ET Operator Continue reading For further details see: Merck (MRK) Q1 2024 Earnings Call Transcript
2024-04-25 14:15:29 ET Merck & Co., Inc. (MRK) Q1 2024 Results Conference Call April 25, 2024 09:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs ...
2024-04-25 07:56:55 ET More on Bristol-Myers Squibb Company Is Bristol Myers Squibb A Buy At These Bottom Levels? Bristol-Myers Squibb: Market Pessimism Won't Last Forever Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade) Bristol-...
2024-04-25 07:10:53 ET More on Merck Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck Non-GAAP EPS of $2....
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
2024-04-25 06:59:26 ET More on Merck Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck Non-GAAP EPS of $2....
2024-04-25 06:32:23 ET More on Merck Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck Q1 Earnings Preview...
News, Short Squeeze, Breakout and More Instantly...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
New Phase 3 data evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate, in previously treated locally recurrent or metastatic triple-negative breast cancer First presentation of Phase 2b three-year follow-up data evaluating mRNA-4157 (V940...
Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor...